Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease

Curr Opin Lipidol. 2013 Apr;24(2):189-90. doi: 10.1097/MOL.0b013e32835ec5f5.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Benzhydryl Compounds
  • Blood Pressure / drug effects
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucosides / pharmacology
  • Humans
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / metabolism
  • Hypoglycemic Agents / pharmacology*
  • Risk Factors
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Treatment Outcome

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • dapagliflozin
  • Glucagon-Like Peptide 1